Nephros, Inc.

Good day and welcome to the Nefros, Inc. Fourth Quarter 2021 Financial Results Conference Call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note, this event is being recorded. I would now like to turn the conference over to Kieran Smith with PCG Advisory. Please go ahead.

Good afternoon, everyone. This is Kieran Smith with PCG Advisory. Thank you all for participating in NEPHRO's fourth quarter 2021 conference call. Before we begin, I would like to caution that comments made during this conference call by management will contain forward-looking statements regarding the operations and future results of Nefros. I encourage you to review Nefros' filings with the Securities and Exchange Commission, including, without limitation, the company's forms 10-K and 10-Q, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Factors that may affect the company's results include, but are not limited to, the impact of the COVID-19 pandemic, Nefros' ability to successfully, timely, and cost-effectively develop, seek, and obtain regulatory clearance for its products and services offerings, the rate of adoption of its products and services by hospitals and other healthcare providers, success of its commercialization efforts, and its effect on the business of existing and new regulatory requirements, and other economic and competitive factors. The content of this conference call contains time-sensitive information that is accurate only as of the date of the live call, today, February 23rd, 2022. The company undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call, except as required by law. I would now like to turn the call over to NetROSA's President and Chief Executive Officer, Andy Astor. Andy, please go ahead.

Thank you, Karen, and good afternoon, everyone. With me on the call today is Wes Lobo, our Chief Commercial Officer. Some of you might recall that Wes joined Nefros a little over a year ago and happy anniversary, Wes. And I thought it would be beneficial for you all to hear what he and his teams have been working on. I will begin the call with a summary of Nefros' recent progress toward its revenue guidance of 25 to 30% growth or 13 to 13 and a half million dollars. I am pleased to report that we've had a strong start to the first few weeks of 2022. And to name a few examples, number one, we are now shipping filters on a nationally recognized quick service restaurant deal, which will add about $250,000 in revenues in 2022. We also continue to pursue several other large opportunities in the food service and beverage industries. Two. We have become a strategic supplier for two major dialysis companies. We expect these deals to add at least half a million or $500,000 in revenue over the next 12 months. Other significant dialysis customers are also in the pipeline. Three, we are making excellent progress in our pathogen detection systems group, including significant commercial discussions with at least three leading firms in the microbiological testing space. Also, as noted in our recent shareholder letter, PDS, our pathogen detection group, has achieved CDC's ELITE certification for our laboratories, which has helped establish nephros as a leading developer and manufacturer of QPCR assays for both environmental and RUO, or research use only, testing. Four, with respect to specialty renal products, or SRP, and the HDF Assist Module, we have completed our responses on 10 of the 14 topics raised by the FDA and are on schedule to resubmit for 510 clearance by the end of this quarter, Q1. Based on our high level of confidence, we have just hired an SRP Director of Commercial Operations whose job will be to manage the commercial launch of the HDF Assist Module and all aspects of the sales, marketing, logistics, and training related to the commercial launch of HDF. Five, we are planning to launch our new website and lead generation infrastructure in the next 45 to 60 days. And six, finally, our core business and hospital filtration sales remain strong, including customer retention rates exceeding 90%, and adding an average of more than one new customer site every day. We believe all of the above points are strong indicators of progress and are cause for optimism. To be clear, though, not all of these will be showing significant results in Q1 or even Q2. Building scalability will have a bigger return in the second half of 2022, and more importantly, sets us up for sustainable growth in the long run. I will say this. The Nefros leadership team is working tirelessly to deliver tangible results in the coming months to return us to the growth performance you have come to expect from Nefros, and that we all believe that we can deliver. So I'll now turn the call over to Wes Lobo, our Chief Commercial Officer, for a closer look at some of our sales and marketing activities, and then I'll return to review our financial results. Wes, please go ahead.